Oui, sans traitement, les troubles cognitifs peuvent s'aggraver avec le temps.
Troubles cognitifsAggravation des symptômes
#3
Y a-t-il un risque accru de maladies associées ?
Oui, les troubles de clathrine peuvent augmenter le risque de maladies métaboliques.
Maladies métaboliquesRisque accru
#4
Des problèmes de développement peuvent-ils survenir ?
Oui, des retards de développement peuvent être observés chez certains patients.
Retards de développementProblèmes de développement
#5
Les complications sont-elles réversibles ?
Certaines complications peuvent être gérées, mais pas toutes sont réversibles.
Complications gérablesRéversibilité
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour les troubles de clathrine ?
Les facteurs génétiques et environnementaux peuvent influencer le risque.
Facteurs génétiquesFacteurs environnementaux
#2
L'âge est-il un facteur de risque ?
Oui, certains troubles peuvent se manifester plus tard dans la vie.
ÂgeManifestation des troubles
#3
Les antécédents familiaux jouent-ils un rôle ?
Oui, des antécédents familiaux de troubles neurologiques peuvent augmenter le risque.
Antécédents familiauxTroubles neurologiques
#4
Le mode de vie influence-t-il le risque ?
Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque.
Mode de vie sédentaireMauvaise alimentation
#5
Les infections peuvent-elles être un facteur de risque ?
Certaines infections virales peuvent potentiellement affecter la fonction cellulaire.
Infections viralesFonction cellulaire
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines d'assemblage monomériques de la clathrine : Questions médicales les plus fréquentes",
"headline": "Protéines d'assemblage monomériques de la clathrine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines d'assemblage monomériques de la clathrine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-21",
"dateModified": "2025-03-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines d'assemblage monomériques de la clathrine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines adaptatrices du transport vésiculaire",
"url": "https://questionsmedicales.fr/mesh/D033942",
"about": {
"@type": "MedicalCondition",
"name": "Protéines adaptatrices du transport vésiculaire",
"code": {
"@type": "MedicalCode",
"code": "D033942",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.990.150"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéines d'assemblage monomériques de la clathrine",
"alternateName": "Monomeric Clathrin Assembly Proteins",
"code": {
"@type": "MedicalCode",
"code": "D034041",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Liping Wang",
"url": "https://questionsmedicales.fr/author/Liping%20Wang",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Jeanne C Stachowiak",
"url": "https://questionsmedicales.fr/author/Jeanne%20C%20Stachowiak",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, United States."
}
},
{
"@type": "Person",
"name": "Margaret E Johnson",
"url": "https://questionsmedicales.fr/author/Margaret%20E%20Johnson",
"affiliation": {
"@type": "Organization",
"name": "TC Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, Maryland, United States of America."
}
},
{
"@type": "Person",
"name": "Min Wu",
"url": "https://questionsmedicales.fr/author/Min%20Wu",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Biology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520-8002, USA. Electronic address: wu.min@yale.edu."
}
},
{
"@type": "Person",
"name": "Chun Wan",
"url": "https://questionsmedicales.fr/author/Chun%20Wan",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, CO 80309, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.",
"datePublished": "2022-11-13",
"url": "https://questionsmedicales.fr/article/36371582",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12760-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Feasibility of local therapy for recurrent pancreatic cancer.",
"datePublished": "2022-05-24",
"url": "https://questionsmedicales.fr/article/35641368",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pan.2022.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ultrasound Assessment of Skin Tumors Local Recurrence.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37195073",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jum.16255"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37442715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejso.2023.06.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36371607",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/his.14839"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines du transport vésiculaire",
"item": "https://questionsmedicales.fr/mesh/D033921"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines adaptatrices du transport vésiculaire",
"item": "https://questionsmedicales.fr/mesh/D033942"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protéines d'assemblage monomériques de la clathrine",
"item": "https://questionsmedicales.fr/mesh/D034041"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines d'assemblage monomériques de la clathrine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines d'assemblage monomériques de la clathrine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines d'assemblage monomériques de la clathrine",
"description": "Comment diagnostiquer une anomalie des protéines de clathrine ?\nQuels examens sont recommandés pour évaluer la clathrine ?\nY a-t-il des biomarqueurs associés aux protéines de clathrine ?\nQuels symptômes peuvent indiquer un problème de clathrine ?\nLes tests d'imagerie sont-ils utiles pour la clathrine ?",
"url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Neoplasm+Recurrence,+Local#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines d'assemblage monomériques de la clathrine",
"description": "Quels symptômes sont liés à une dysfonction de la clathrine ?\nLa fatigue est-elle un symptôme associé ?\nDes douleurs musculaires peuvent-elles survenir ?\nY a-t-il des symptômes neurologiques associés ?\nLes troubles de la vision sont-ils possibles ?",
"url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Neoplasm+Recurrence,+Local#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines d'assemblage monomériques de la clathrine",
"description": "Comment prévenir les troubles liés à la clathrine ?\nY a-t-il des tests de dépistage recommandés ?\nLes vaccinations peuvent-elles aider ?\nLe stress peut-il affecter la clathrine ?\nDes conseils de mode de vie sont-ils disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Neoplasm+Recurrence,+Local#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines d'assemblage monomériques de la clathrine",
"description": "Quels traitements sont disponibles pour les troubles de clathrine ?\nDes médicaments spécifiques existent-ils ?\nLa thérapie génique est-elle une option ?\nLes suppléments nutritionnels peuvent-ils aider ?\nLa rééducation est-elle recommandée ?",
"url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Neoplasm+Recurrence,+Local#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines d'assemblage monomériques de la clathrine",
"description": "Quelles complications peuvent survenir avec des troubles de clathrine ?\nLes troubles cognitifs peuvent-ils s'aggraver ?\nY a-t-il un risque accru de maladies associées ?\nDes problèmes de développement peuvent-ils survenir ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Neoplasm+Recurrence,+Local#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines d'assemblage monomériques de la clathrine",
"description": "Quels sont les facteurs de risque pour les troubles de clathrine ?\nL'âge est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie influence-t-il le risque ?\nLes infections peuvent-elles être un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D034041?mesh_terms=Neoplasm+Recurrence,+Local#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des protéines de clathrine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses protéomiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour évaluer la clathrine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunoblot et la microscopie électronique sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés aux protéines de clathrine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de biomarqueurs spécifiques largement reconnus."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème de clathrine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques ou des anomalies métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests d'imagerie sont-ils utiles pour la clathrine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'imagerie ne sont pas spécifiques pour les protéines de clathrine."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysfonction de la clathrine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la motricité, des problèmes cognitifs et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme associé ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue peut être un symptôme indirect d'une dysfonction cellulaire."
}
},
{
"@type": "Question",
"name": "Des douleurs musculaires peuvent-elles survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent être liées à des anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des convulsions ou des troubles de l'équilibre peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les troubles de la vision sont-ils possibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la vision peuvent survenir en raison de dysfonctionnements neuronaux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés à la clathrine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir certains troubles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests de dépistage recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de tests de dépistage spécifiques pour ces troubles."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne sont pas directement liées à la prévention des troubles de clathrine."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter la clathrine ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut avoir un impact négatif sur la santé cellulaire en général."
}
},
{
"@type": "Question",
"name": "Des conseils de mode de vie sont-ils disponibles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conseils incluent l'exercice régulier et la gestion du stress."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles de clathrine ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements sont symptomatiques et peuvent inclure des thérapies physiques."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques existent-ils ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de médicaments spécifiques ciblant directement les protéines de clathrine."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible."
}
},
{
"@type": "Question",
"name": "Les suppléments nutritionnels peuvent-ils aider ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments peuvent aider à gérer les symptômes, mais pas à traiter la cause."
}
},
{
"@type": "Question",
"name": "La rééducation est-elle recommandée ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la rééducation physique peut aider à améliorer la fonction motrice."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des troubles de clathrine ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et métaboliques peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les troubles cognitifs peuvent-ils s'aggraver ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement, les troubles cognitifs peuvent s'aggraver avec le temps."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies associées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les troubles de clathrine peuvent augmenter le risque de maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Des problèmes de développement peuvent-ils survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des retards de développement peuvent être observés chez certains patients."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais pas toutes sont réversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles de clathrine ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques et environnementaux peuvent influencer le risque."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles peuvent se manifester plus tard dans la vie."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de troubles neurologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent potentiellement affecter la fonction cellulaire."
}
}
]
}
]
}
Little information is available about the clinical and pathologic characteristics of local recurrence (LR) after nipple-sparing mastectomy according to the locations of LR....
This study classified 99 patients into the following two groups according to the location of LR after nipple-sparing mastectomy: nipple-areolar recurrence (NAR) group and other locations of LR (oLR) g...
For about half of the patients (44.4 %) with NAR, the primary cancer was estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-positive. Conversely, in most of the patien...
This multi-institutional retrospective study demonstrated that the features of NAR, such as the characteristics of the primary and recurrent tumors and the prognostic factors after LR resection, were ...
Despite advances in perioperative management, recurrence after curative pancreatectomy is a critical issue in the treatment of pancreatic ductal adenocarcinoma (PDAC). The significance of local therap...
We reviewed the medical records of patients with PDAC who underwent curative resection at our institution between January 2009 and December 2019. We examined the patterns of relapse and assessed the c...
A total of 246 patients with PDAC who underwent R0 or R1 resection were included in this study. The 3-year overall survival (OS) rate was 39.8%, and the 1-year recurrence-free survival rate was 51.2% ...
Our results suggest that a multimodal approach may improve the clinical outcomes of patients with recurrent PDAC....
Skin cancer may recur at or around the surgical site despite wide excisions. Prompt clinical and sonographic detection of local recurrence is important since subjects with relapsing melanomas or nonme...
Pathological factors that influence and predict survival following pelvic exenteration (PE) for locally advanced (LARC) or locally recurrent rectal cancer (LRRC), especially LRRC, remain poorly unders...
A retrospective cohort study was performed for all patients undergoing a curative PE for LARC or LRRC between 2008 and 2021 at a tertiary referral UK specialist colorectal hospital. Cox regression ana...
388 patients were included in the analysis with 256 resections for LARC and 132 for LRRC. 62.4% of patients were male with a median age of 59 years (IQR 49-67). 247 (64%) partial pelvic exenterations ...
A positive resection margin and poorly differentiated tumours are significant negative prognostic markers for survival and recurrence in LARC. The results of this study support the need to look for al...
Using CODA, a technique for three-dimensional reconstruction of large tissues, Kiemen et al. report observation of a microscopic focus of pancreatic cancer found in the vasculature of grossly normal h...
The initial approach to the treatment of desmoid tumors has changed from surgical resection to watchful waiting. However, surgery is still sometimes considered for some patients, and it is likely that...
We sought to explore whether a combined molecular and clinical prognostic model for relapse in patients with desmoid tumors treated with surgery would allow us to identify patients who might do well w...
This was a retrospective, single-center study of 107 patients with desmoid tumors who were surgically treated between January 1980 and December 2015, with a median follow-up of 106 months (range 7 to ...
The multivariable analysis showed that S45F mutations (hazard ratio 5.25 [95% confidence interval 2.27 to 12.15]; p < 0.001) and tumor in the extremities (HR 3.15 [95% CI 1.35 to 7.33]; p = 0.008) wer...
CTNNB1 S45F mutations combined with other clinical variables are a potential prognostic biomarker associated with the risk of relapse in patients with desmoid tumors. The developed nomogram is simple ...
Level III, therapeutic study....
A first local recurrence is common after resection or radiotherapy for brain metastasis (BM). However, patients with BMs can develop multiple local recurrences over time. Published data on second loca...
Patients were identified from a database at Brigham and Women's Hospital in Boston. Hazard ratios and 95% confidence intervals for predictors of a second local recurrence were computed using a Cox pro...
Of 170 identified surgically treated first locally recurrent lesions, 74 (43.5%) progressed to second locally recurrent lesions at a median of 7 months after craniotomy. Subtotal resection of the firs...
A second local recurrence occurred after 43.5% of craniotomies for first recurrent lesions. Subtotal resection and infratentorial location were the strongest risk factors for worse second local recurr...
The current study was undertaken to provide more detailed prognostic models for early prediction of local recurrences and local recurrence free survival (RFS) using different radiologic and pathologic...
One hundred patients with locally advanced rectal carcinomas decided to receive neoadjuvant CRT were retrospectively recruited, Hazard ratios (HR) were determined in the two cox regression models and ...
HR of 1st group of models: T+N, T+N+G, T+N+G+S, T+N+G+S+PNI, and T+N+G+S+PNI+R were summated and categorized into scores, these scores were significantly correlated with the risk of recurrence (Somer'...
We propose that the addition of biologic factors to staging of rectal cancer provide precise stratification and association with local recurrences in patients received preoperative CRT....
This study aims to identify prognostic factors and define the best extent of surgery for optimizing treatment of local recurrence (LR) following colorectal cancer (CRC)....
An institutional database of consecutive patients who underwent radical resection (R0/R1) of LR following CRC was analyzed prospectively from 2010 to 2021 at one tertiary cancer center....
In this study, 75 patients were included with LR following CRC and analyzed. Patients were categorized as compartmental resections (CompRe) (n = 47) if all adjacent organs were systematically removed,...
Complete compartmental surgery is safe and improves local control. Optimal LR resection needs to remove all contiguous organs, with or without tumor involvement....
RET-fused mesenchymal neoplasms mostly affect the soft tissue of paediatric patients. Given their responsiveness to selective RET inhibitors, it remains critical to identify those extraordinary cases ...
Clinicopathological features were assessed and partner agnostic targeted next-generation sequencing on clinically validated platforms were performed. The patients were 18, 53, and 55 years old and inc...
Our study expands the clinicopathological and genetic spectrum of mesenchymal neoplasms associated with RET fusions....
